L, S., A, C., M, C., D, C., M, D., F, H., . . . S, A. (2023). Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. Journal of managed care & specialty pharmacy, 29(11), 1205. https://doi.org/10.18553/jmcp.2023.23031
Chicago Style (17th ed.) CitationL, Sanchez, et al. "Comparison of Health Care Costs and Resource Utilization for Commonly Used Proteasome Inhibitor-immunomodulatory Drug-based Triplet Regimens for the Management of Patients with Relapsed/refractory Multiple Myeloma in the United States." Journal of Managed Care & Specialty Pharmacy 29, no. 11 (2023): 1205. https://doi.org/10.18553/jmcp.2023.23031.
MLA (9th ed.) CitationL, Sanchez, et al. "Comparison of Health Care Costs and Resource Utilization for Commonly Used Proteasome Inhibitor-immunomodulatory Drug-based Triplet Regimens for the Management of Patients with Relapsed/refractory Multiple Myeloma in the United States." Journal of Managed Care & Specialty Pharmacy, vol. 29, no. 11, 2023, p. 1205, https://doi.org/10.18553/jmcp.2023.23031.
